Related Experiment Video
Updated: May 10, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Familial hemiplegic migraine in Indian children-a tertiary center experience
Lokesh Saini1, Pradeep Kumar Gunasekaran1, Sarbesh Tiwari2
1Department of Pediatrics, All India Institute of Medical Sciences, Jodhpur 342005, Rajasthan, India.
Insights
Familial hemiplegic migraine (FHM) in children presents with hemiparesis and headache. Genetic testing confirmed mutations, and topiramate showed favorable treatment responses in this study.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Familial hemiplegic migraine (FHM) is a rare, autosomal dominant subtype of migraine with aura.
- It is a neurological channelopathy characterized by severe headache, hemiplegia, and other neurological deficits.
- FHM presents significant diagnostic challenges, particularly in pediatric populations.
Purpose of the Study:
- To investigate the clinical presentation, genetic basis, and treatment response of familial hemiplegic migraine in children.
- To highlight the diagnostic delay and neuroimaging findings in pediatric FHM cases.
- To evaluate the efficacy of topiramate in managing FHM symptoms in children.
Main Methods:
- A cross-sectional study involving children aged 1-18 years suspected of FHM.
- Clinical data collection, including neurological symptoms and episode duration.
- Genetic testing for FHM-associated genes (ATP1A2, SCN1A) and neuroimaging (MRI T2/FLAIR).
- Treatment with oral topiramate and follow-up assessment.
Main Results:
- Five children with genetically confirmed FHM were included, presenting with hemiparesis, headache, and focal seizures.
- Mean age at onset was 6.8 years, with a significant diagnostic delay of 6.1 years.
- Neuroimaging showed accentuated gray-white differentiation; genetic testing revealed ATP1A2 and SCN1A mutations.
- All patients responded favorably to oral topiramate treatment.
Conclusions:
- Familial hemiplegic migraine diagnosis in children is primarily clinical, supported by genetic analysis.
- MRI, especially perfusion and diffusion-weighted sequences, can aid diagnosis during acute episodes.
- Topiramate is an effective treatment option for pediatric FHM, demonstrating favorable outcomes.
Abstract:
Familial hemiplegic migraine (FHM), an autosomal dominant subtype of hemiplegic migraine, is a channelopathy presenting with severe headache, visual field defect, paresthesia, unilateral motor deficit, encephalopathy, seizures and aphasia. This cross-sectional study was conducted over 10 months in children aged 1-18 years suspected of hemiplegic migraine at a tertiary care pediatric hospital. Fourteen children were screened and five children with genetically confirmed FHM were included. The symptoms in the study population were paroxysmal hemiparesis (5/5), headache (5/5) and focal seizures (1/5). The hemiplegia episodes lasted from 4 h to 7 days. The mean age at the onset of neurological symptoms was 6.8 ± 0.7 years and the mean age at diagnosis was 12.8 ± 1.7 years, with a mean delay of 6.1 ± 1.9 years for the diagnosis. Neuroimaging during acute episodes revealed accentuated gray, white differentiation in the contralateral cerebral hemisphere with mild effacement of sulcal spaces in T2/fluid-attenuated inversion recovery (FLAIR) images. Genetic testing revealed ATP1A2 mutations (FHM2) in 4/5 and SCN1A (FHM3) in 1/5 patients. All of them (5/5) were initiated on oral topiramate and had favorable treatment responses with a mean follow-up duration of 7 ± 1.4 months. Diagnosis of FHM is mainly clinical and can be confirmed by genetic analysis. Perfusion and diffusion-weighted MRI should be considered during acute headache episodes, as it is mostly normal in symptom-free periods. Routine MRI sequences like T1 weighted, T2 weighted, FLAIR and contrast remain normal even during acute attacks.
More Related Videos
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Related Concept Videos
Viral Meningitis
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Bacterial Meningitis I: Introduction
Encephalitis l: Introduction
Increased Intracranial Pressure l: Introduction